Equities analysts forecast that Voyager Therapeutics Inc (NASDAQ:VYGR) will announce earnings per share of ($0.76) for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Voyager Therapeutics’ earnings. The highest EPS estimate is ($0.46) and the lowest is ($0.91). Voyager Therapeutics posted earnings per share of ($0.89) in the same quarter last year, which suggests a positive year-over-year growth rate of 14.6%. The company is expected to announce its next earnings results on Thursday, November 1st.
On average, analysts expect that Voyager Therapeutics will report full-year earnings of ($3.12) per share for the current financial year, with EPS estimates ranging from ($3.41) to ($2.43). For the next year, analysts expect that the business will report earnings of ($3.39) per share, with EPS estimates ranging from ($4.29) to ($2.60). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Voyager Therapeutics.
Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Tuesday, August 7th. The company reported ($0.80) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.13). The business had revenue of $2.58 million for the quarter, compared to analyst estimates of $3.00 million. Voyager Therapeutics had a negative net margin of 731.88% and a negative return on equity of 80.68%.
Shares of NASDAQ:VYGR traded up $0.43 during midday trading on Friday, hitting $16.13. 256,414 shares of the company’s stock traded hands, compared to its average volume of 412,275. The firm has a market capitalization of $613.69 million, a price-to-earnings ratio of -6.11 and a beta of 2.94. Voyager Therapeutics has a twelve month low of $11.54 and a twelve month high of $31.91.
In other news, Director James A. Geraghty purchased 3,000 shares of the company’s stock in a transaction that occurred on Monday, September 10th. The shares were purchased at an average price of $19.39 per share, with a total value of $58,170.00. Following the purchase, the director now directly owns 76,588 shares of the company’s stock, valued at approximately $1,485,041.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Glenn Pierce purchased 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 12th. The shares were purchased at an average cost of $18.44 per share, for a total transaction of $92,200.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 11,000 shares of company stock worth $205,300 in the last ninety days. 33.60% of the stock is currently owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in the stock. BB Biotech AG increased its stake in Voyager Therapeutics by 27.1% during the 2nd quarter. BB Biotech AG now owns 2,532,641 shares of the company’s stock worth $49,488,000 after buying an additional 540,000 shares during the period. BlackRock Inc. increased its stake in Voyager Therapeutics by 28.3% during the 2nd quarter. BlackRock Inc. now owns 1,845,706 shares of the company’s stock worth $36,066,000 after buying an additional 407,677 shares during the period. Farallon Capital Management LLC increased its stake in Voyager Therapeutics by 35.9% during the 1st quarter. Farallon Capital Management LLC now owns 890,000 shares of the company’s stock worth $16,723,000 after buying an additional 235,188 shares during the period. Millennium Management LLC increased its stake in Voyager Therapeutics by 124.0% during the 1st quarter. Millennium Management LLC now owns 618,021 shares of the company’s stock worth $11,613,000 after buying an additional 342,148 shares during the period. Finally, Wells Fargo & Company MN increased its stake in Voyager Therapeutics by 15.2% during the 2nd quarter. Wells Fargo & Company MN now owns 450,480 shares of the company’s stock worth $8,802,000 after buying an additional 59,497 shares during the period. 89.64% of the stock is currently owned by hedge funds and other institutional investors.
About Voyager Therapeutics
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.
Featured Story: What is intrinsic value?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.